The first agent in a new class of drugs may offer some relief from the hallucinations and delusions of Parkinson disease psychosis.
Recent data show that pimavanserin, a selective serotonin 5-HT2A inverse agonist, provided significant antipsychotic benefit to 199 patients with Parkinson disease psychosis treated at 54 clinical trial sites in the United States and Canada. Patients randomly received 40 mg of pimavanserin or a placebo for 6 weeks. At day 43 of the study, an analysis showed that symptoms improved by 37% in patients who received pimavanserin compared with 14% in the placebo group.
From JAMA’s Daily News Site. JAMA. 2014;311(5):455. doi:10.1001/jama.2014.24